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Effect of prostanoids on renin release from rabbit afferent arterioles
with and without macula densa. There is evidence that cyclooxygenase
products of arachidonic acid participate in the control of renin release.
In this study we tested the hypothesis that prostaglandin (P0)12 and/or
its metabolite(s), which are synthesized in the afferent arteriole (AF),
stimulate renin release by acting directly on the AF while POE2
stimulates renin release indirectly via the macula densa. AF alone and
AF with macula densa attached (AF-MD) were microdissected from
rabbit kidneys and incubated in vitro. The renin release rate from a
single AF (or an AF-MD) was calculated and expressed as ng
AL . hr' AW*hr (where AL is angiotensin I). When arachidonic acid
(0.12 mM) or P012 (10 j.tM) was added to AF, renin release increased
significantly (Pc 0.0001) from 1.04 0.21 to 3.12 0.86 (,i saM, N
= 7), and from 0.45 0.14 to 1.48 0.53 (N = 9), respectively. During
the recovery period, renin release increased even further, reaching 9.53
1.76 and 4.50 1.24, respectively. A P012 synthetase inhibitor, 9,
1 l-azoprosta-5,l3-dienoic acid blocked the effect of arachidonic acid.
To examine whether the increases in renin release during the recovery
period were due to metabolite(s) of P012, we tested the effect of both
6-keto-PGE1 (an active metabolite of P012) and carba-P012 (a synthetic
analog that is metabolized differently from P012). Six-keto-PGE1 and
carba-POI2 increased renin release only during the experimental period
with no further increase during the recovery period. When POE2 (14
/LM) was added to AT alone, renin release did not change significantly;
however, when it was added to AF-MD, renin release increased by
133%, going from 0.54 0.09 to 1.26 0.24 (N = 8, P c 0.02). These
results suggest that AF synthesizes PG!2 and possibly its metabolite(s),
which in turn stimulate renin release by acting directly on AF, whereas
POE2 stimulates renin release indirectly via the macula densa.
There is evidence that cyclooxygenase products of arachi-
donic acid participate in the control of renin release [1—41.
Although various prostaglandins (PGs) have been shown to
stimulate renin release both in vivo and in vitro, evidence
supports PG!2 as the mediator of the PG-dependent renin
releasing mechanism [5—7], PG!2 is the main PG synthesized by
the renal cortical blood vessesl [8, 9]. Thus afferent arterioles,
where the juxtaglomerular cells synthesize and store renin, may
also produce P012 which could in turn participate in the control
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of renin release. On the other hand, POE2 appears to be the
principal PG synthesized by renal tubular and medullary inter-
stitial cells [101, and it has been hypothesized that POE2 could
stimulate renin release by altering electrolyte transport at the
level of the macula densa [11]. However, there is no direct
evidence to support this hypothesis.
In the present study, we tested the hypothesis that P012 and!
or its metabolite(s) are synthesized in the afferent arterioles and
act on them to stimulate renin release, whereas POE2 stimulates
renin release indirectly via the macula densa. For this purpose,
we microdissected rabbit afferent arterioles with and without
macula densa attached [12—14], and incubated the structures in
vitro. Using these two preparations, we examined first whether
altering endogenous synthesis of P012 in the afferent arterioles
affects renin release, second the effects of P0!2, 6-keto-PGE,
(an active metabolite of P012) and carba-P012 (a synthetic
analog that is metabolized differently from POT2) on renin
release from afferent arterioles, and third the effect of POE2 on
renin release from afferent arterioles both with and without
macula densa attached.
Methods
Protocols 1 through 6 were performed in Detroit, Michigan,
USA, and protocols 7 and 8 in Sendai, Japan. The following
materials were obtained commercially and used in protocols 1
through 6: medium 199, Gibco Laboratories (Orand Island,
New York, USA); bovine serum albumin (BSA), Schwarz!
Mann (Orangeburg, New York, USA); sodium heparin (1,000
U!ml), Elkins-Sinn, Inc. (Cherry Hill, New Jersey, USA);
sodium pentobarbital (Nembutal, 50 mg!mI), Abbott Laborato-
ries (North Chicago, Illinois, USA); arachidonic acid (sodium
salt), Calbiochem-Behring Corp. (La Jolla, California, USA);
POE2, PGI2 and 6-keto-PGE,, Sigma Chemical (St. Louis,
Missouri, USA); and carba-PGI2, Cayman Chemical (Ann
Arbor, Michigan, USA). Upjohn Pharmaceutical Co. supplied a
P012 synthetase inhibitor, 9,11 -azoprosta-5, 13-dienoic acid
(azo analog 1). The following materials were obtained commer-
cially and used in protocols 7 and 8: Eagle minimal essential
medium (MEM), Nissui Pharmaceutical Co. (Tokyo, Japan);
sodium heparin, Novo Industries (Denmark); sodium pentobar-
bital, Abbott Laboratories; bovine serum albumin (BSA), Wako
Pure Chemical Industries L.T.D. (Osaka, Japan); and POE2,
Sigma Chemical.
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Isolation and incubation of afferent arterioles with and
without macula densa attached
The methods for the isolation and incubation of afferent
arterioles, both with and without macula densa attached, have
been described previously [12—14]. Young male, New Zealand
white rabbits (N = 45) were used in protocols 1 through 6, and
young Japanese white rabbits (N = 16) in protocols 7 and 8. We
have previously shown that the basal renin release rate and
renin response to isoproterenol in isolated afferent arterioles are
similar in both strains [15].
Rabbits (1.5 to 2.5 kg) maintained on a standard rabbit chow
and tap water ad libitum were anesthetized with sodium pento-
barbital (40 mg/kg, i.v.) and given an intravenous injection of
heparin. The left kidney was perfused in situ with cold, oxy-
genated (95% 02 and 5% C02) medium (medium 199 and MEM
in protocols I to 6 and 7 and 8, respectively) containing 0.1%
BSA. The kidney was then removed and sliced along the
corticomedullary axis. Slices were placed in ice-cold medium
and microdissected at 4°C under a stereomicroscope at magni-
fications up to lOOx.
Superficial afferent arterioles with or without macula densa
attached, arising from the terminus of the interlobular arteries,
were microdissected in 90 minutes. The afferent arterioles were
severed from the interlobular arteries and glomeruli using
hypodermic needles (26 to 30 gauge). Care was taken to avoid
the distortion of arterioles or the disruption of vascular poles.
During the microdissection of afferent arterioles with macula
densa attached, the thick ascending limb of the 1oop of Henle
and the distal convoluted tubule were each gently pulled off at
a point less than 50 m from the macula densa.
In protocols 1 through 6, approximately ten afferent arterioles
alone were microdissected, and divided into control and exper-
imental groups of five afferent arterioles each. The afferent
arterioles in each group were transferred into a small plastic
ladle that had a nylon mesh bottom (54 sm; Tetko, Inc.,
Elmsford, New York, USA), and the ladles were preincubated
at 37°C in 7 ml of oxygenated medium containing 0.1% BSA
(medium-0. 1% BSA) for 35 minutes. After preincubation, each
ladle was rinsed, blotted, and transferred into a small plastic
microtube containing 100 d of oxygenated medium-0. 1% BSA.
The gas layer above the incubation medium was replaced with
95% 02 and 5% C02, and the microtubes were covered tightly.
The afferent arterioles were incubated in medium-0. 1% BSA for
the first 15 minutes (control period), after which the ladles were
transferred to fresh medium-0. 1% BSA containing either the
drug to be tested or its vehicle for the second 15-minute
incubation (experimental period). Following the experimental
period, arterioles were again placed in medium-0. 1% BSA for
the 15-minute recovery period. In protocols 7 and 8, approxi-
mately five afferent arterioles both with and without macula
densa attached were microdissected and incubated for control
and experimental periods as described above; each incubation
period was 20 minutes, and the recovery period was omitted.
Incubation medium left in the microtube was frozen (—20°C)
until the renin assay was performed. After serial incubations
were completed, it was confirmed microscopically that all
microdissected structures remained in the ladle. For the deter-
mination of tissue renin content, these incubated afferent arte-
rioles with or without macula densa were placed in 1 ml of
medium-0. 1% BSA and immediately frozen. After freezing and
thawing were repeated five times, the tissue samples were
stored frozen until tissue renin content was determined.
Experimental protocol
1. Time control. Afferent arterioles were incubated in me-
dium 199 containing 0.1% BSA for three 15-minute periods
concurrently with each of the protocols 2 through 6. The proper
vehicle was added to the incubation medium used during the
experimental period. Medium 199 had the following composi-
tion: Nat, 133 mEq/liter; K, 5.4 mEq/liter; C1, 125 mEq/liter;
Ca2, 3.6 mEqfliter; HC03, 14.9 mM; H2P04, 1.0 mM;
HEPES 25 mM.
2. Arachidonjc acid. Arachidonic acid (final concentration
1.2 x l0— M) was added to the incubation medium used during
the experimental period.
3. PGI synthetase inhibitor plus arachidonic acid. In order
to determine the importance of PGI2 in arachidonic acid-
induced renin release, afferent arterioles were pretreated with a
PGI2 synthetase inhibitor, 9,11 -azoprosta-5, 13-dienoic acid
(azo analog 1) at a concentration of 2.8 X l0_6 M, which has
been shown to block PG!2 synthesis [5, 7]. Azo analog 1 was
added to the incubation media used during the preincubation,
control, experimental and recovery periods. Arachidonic acid(1.2 x l0 M) or its vehicle was added to the incubation
medium used during the experimental period.
4. Prostaglandin '2 PG!2 (final concentration 1.0 x iO M)
was added to the incubation medium used during the experi-
mental period. It was dissolved in a solution containing nine
parts of ethanol and one part of 0.05 M tris buffer (pH 9.0) and
stored at —70°C (3.0 x lO— M). This stock solution was diluted
to 1.0 x l0— M with ice-cold 0.5 M tris buffer, pH 9.0 and
further diluted to 1.0 x 10 M with oxygenated medium-0. 1%
BSA immediately before use.
5. Carba-prostaglandin '2 Since renin responses to both
arachidonic acid and PG!2 were greater during the recovery
period than during the experimental period (Results), we tested
whether the continued increases in renin release during the
recovery period are mediated by metabolite(s) of PGI2. Carba-
PGI2, a synthetic analog of PG!2. was added to the incubation
medium used during the experimental period (final concentra-
tion 5.0 x l0 M). Although carba-PGI2 may be metabolized
[16, 17], at least some of the metabolites of PGI2, such as
6-keto-PGF1 and 6-keto-PGE1, will not be formed from carba-
PG!2. Carba-PG!2 was dissolved in 100% ethanol (5.0 x 102 M)
and stored at —20°C. This stock solution was diluted to the final
concentration of 5.0 x l0 M with oxygenated medium-0. 1%
BSA, and it was used immediately.
6. Six-keto-prostaglandin E,. Six-keto-PGE1, an active me-
tabolite of PGI2, was added to the incubation medium of the
experimental period (final concentration 1.0 x l0— M). It was
dissolved in 100% ethanol, stored at —20°C and protected from
exposure to light. Before use, ethanol was blown out and the
residue was dissolved with medium-0.1% BSA.
7. Time control. Afferent arterioles with and without macula
densa were incubated in MEM containing 0.1% BSA for two
20-minute periods; the recovery period was omitted. MEM had
the following composition: Na, 141 mEq/liter; K, 5.4 mEq/
liter; Cl, 125 mEq/liter; Ca2, 3.6 mEq/liter: HC03, 23.8 mM;
H2P04, 1.0 mM.
1140 Ito et a!: Prostaglandin and renin release
8. Prostaglandin E2. Afferent arterioles, both with and with-
out macula densa, were incubated in MEM containing 0.1%
BSA for the control period and then placed in medium contain-
ing PGE2 (final concentration 1.4 X 10 M) for the experimen-
tal period.
Determination of renin concentration
Renin concentration in the incubation media and tissue
samples was measured as previously described [12]. Briefly,
incubation media and solutions of tissue samples were incu-
bated with partially purified rabbit substrate equivalent to 1,000
ng angiotensin I (Al) at 37°C for three hours (pH 6.5). Gener-
ated Al was measured by radioimmunoassay. Substrate was
prepared by ammonium sulfate fractionation of the plasma
obtained from rabbits nephrectomized 48 hours previously.
Substrate had specific activity ranging from 300 to 700 ng Al/mg
protein, and had no detectable renin or angiotensinase activity.
AT generation was linear with respect to renin concentration
and incubation time up to four hours, and was not affected by
any of the drugs tested in this study.
Renin release rate was calculated as ng Al generated per hour
per arteriole per hour incubation of arteriole (with or without
macula densa), and was expressed as ng A! . hr' 'AF'/hr.
Tissue renin content of a single arteriole (with or without
macula densa) was calculated and expressed as ng Al. hr 1/
AF.
Statistics
All data were expressed as mean SEM. For protocols 1
through 6, profile analysis was used to test whether changes
from control to experimental to recovery periods were different
between groups 1181. Analysis of variance was used to test
whether the values during the recovery period were different
between protocol 6 (carba-PGI2) and protocol 4 (PGI,). Stu-
dent's unpaired t-test was used for the statistical evaluation in
groups 7 and 8. P < 0.05 was considered significant.
Results
Time control. Since the vehicles caused no change in renin
release in any of the time control groups, the data from each
time control experiment were combined. Renin release rates
from afferent arterioles during the control, experimental and
recovery periods were 0.65 0.07, 0.76 0.10 and 0.88 0.11
ng AT . hr . AFVhr, respectively (N = 45). Arteriolar renin
content was 24.3 1.9 ng Al . hr'/AF. Renin release during
the control period was 3.67 0.86% of arteriolar renin content
per hour.
Arachidonic acid. When arachidonic acid was added to
afferent arterioles, renin release rate increased from 1.04 0.21
to 3.12 0.82 ng A! . hr' . AF/hr and continued increasing
to 9.53 1.76 ng A! . hr' . AF'/hr during the recovery
period (P < 0.0001 compared with the time control group; Fig.
1). Arteriolar renin content was 19.5 1.5 ng Al . hr'/AF.
PGI2 synthetase inhibitor plus arachidonic acid. Pretreat-
ment with azo analog 1 did not affect basal renin release rate
(0.40 0.06, 0.50 0.12 and 0.48 0.07 ng Al . hr' . AF'/
hr in the control, experimental and recovery periods, respec-
tively; these values are not statistically significant from those of
time control). However, it prevented the increase in renin
release induced by arachidonic acid at 1.2 x iO M (Fig. 1).
0
Experimental Recovery
Incubation period
Fig. 1. Effects of pretreat,nent with 9,II-azoprosta-5,13-dienoic acid
(azo analog 1), a PG!2 s)'nthetase inhibitor, on basal and arachidonic
acid-induced renin release .from afferent arterioles. Azo analog I at 2.8
)( 106 M was present in the incubation media used during the
preincubation, control, experimental and recovery periods. Arachi-
donic acid (•; N 6; final concentration 1.4 x l0- M) or its vehicle(0; N = 5) was added to the incubation medium used during the
experimental period. The change in renin release caused by arachidonic
acid in no pretreatment group (•; N = 7) was significantly (P < 0.0002)
different from that in the azo analog I pretreatment group.
Prostaglandin '2 When PG!2 was added to afferent arte-
rioles, renin release increased from 0.45 0.14 to 1.48 0.53
ng Al . hr' AF'/hr and continued increasing to 4.50 1.24
ng A! hr . AF/hr during the recovery period (P < 0.0001
compared with the time control group; Fig. 2). Arteriolar renin
content was 35.5 5.5 ng A! . hr'/AF.
Carba-prostaglandin '2 When carba-PGI2 was added to
afferent arterioles, renin release increased from 0.88 0.31 to
1.75 0.49 ng A! . hr' . AF1/hr; renin release stayed at the
same level during the recovery period (1.81 0.59 ng
A! . hr' . AF'/hr; Fig. 2). This change was significant (P <
0.0001) compared with the time control group. The increase (A)
in renin release from the control to the experimental period was
0.87 0,20 ng Al. hr ' . AF/hr in the carba-PGI2 group,
which was not different from that caused by PG!2 (1.04 0.45
ng A!. hr . AF/hr). However, the changes in renin release
over the entire time course were significantly different between
the carba-PGI2 and PG!, groups (P < 0.0001, by profile analy-
sis). Furthermore, renin release rates during the recovery
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Table 1. Effect of prostaglandin E2 on renin release from afferent arterioles with and without attached macula densa
Group No.
Renin release rate
ng Al. hr' AF'/hr
P
Tissue renin
content
ng Al. hr'/AFControl Experimental
Afferent arterioles
Time control
POE2 (1.4 x 1O M)
Afferent arterioles with
8
8
1.13 0.33 1.32 0.40
1.02 0.35 1.17 0.37 NS
33.4 5.9
35.8 11.1
macula densa
Time control
PGE2 (1.4 x iO M)
7
8
0.35 0.06* 0.36 0.06*
0.54 0.09 1.26 0.24 <0.02
49.0 4.9
51.0 13.0
No. refers to the number of experiments in each group. P values were obtained by comparing the changes in renin release from the control to
the experimental period between the time control and PGE2 groups.
a P < 0.05 compared with afferent arterioles alone.
U
Control Experimental Recovery
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Fig. 2. Effects of PG!2 (; N = 9), 6-keto-PGE, (a metabolite ofPGI2;N = 4) and carba-PGI2 (a synthetic analog of PGI2; 0; N = 10) on
renin release from afferent arterioles. PG!2 (1.0 x io— M),6-keto-PGE(1.0 x l0— M) or carba-PG!2 (5.0 X l0 M) was added to the
incubation medium used during the experimental period. The change
induced by PG!2 was significantly different from that induced by
6-keto-PGE1 or carba-PGI2 (P < 0.0001 by profile analysis). *JJ < 0.01
compared with carba-PGI2 group by analysis of variance.
period were also significantly (P < 0.01) different between the
two groups by analysis of variance (Fig. 2). Arteriolar renin
content of the carba-PGI2 group was 20.6 4.85 ng Al . hr 1/
AF.
Six-keto-prostaglandin E1. When 6-keto-PGE1 was added to
afferent arterioles, renin release increased from 0.54 0.07 to
1.80 0.33 ng Al . hr . AF/hr and returned toward the
basal value during the recovery period (0.77 0.13 ngAl. hr' . AF'Ihr; Fig. 2). This change was significant (P <
0.0004) compared with the time control group. Arteriolar renin
content was 118.3 58.0ng Al. hr '/AF. This apparently high
arteriolar renin content was due to one experiment (287.0 ng
Al. hC'/AF), and the value of this group was not statistically
different from that of the time control group.
Time control. Renin release rates from afferent arterioles with
and without macula densa were initially 0.35 0.06 and 1.13
0.33 ng A! . hr' AF/hr, respectively, and they remained
stable during the next incubation period (Table 1). Although the
tissue renin content of afferent arterioles with macula densa
attached was not different from that of afferent arterioles alone,
renin release rate was significantly less in afferent arterioles
with macula densa attached (P < 0.05). Thus, the ratio of renin
release to tissue renin content was significantly smaller (P <
0.05) in the presence (0.58 0.11%) than in the absence of the
macula densa (4.32 1.51%).
Prostaglandin E2. When PGE2 was added to afferent arte-
rioles alone, there was no significant change in renin release (P
> 0.05 compared with the time control group, Table 1). How-
ever, when PGE2 was added to afferent arterioles with macula
densa attached, renin release rate increased by 133% (P < 0.02
compared with the time control group; Table 1, Fig. 3).
Discussion
We have previously shown that microdissected afferent arte-
rioles with and without macula densa attached can be used for
the study of renin release [12—151. The preparation of afferent
arterioles alone allows us to study renin release in the absence
of glomeruli, tubules and macula densa, while the preparation
with macula densa can be used to study the influence of
attached macula densa on renin responses to various sub-
stances. In previous studies [13, 14], we reported that the
attached macula densa has an inhibitory action on renin release,
which appears to be mediated by its endogenous production of
adenosine. The present study was undertaken first to examine
the interaction between PGs and renin release at the local level
of afferent arterioles, and second to examine whether the
macula densa mediates PGE2-induced renin release. Our results
suggest that PG!2 and possibly its metabolite(s), synthesized in
the afferent arterioles, stimulate renin release by acting directly
on the juxtaglomerular cells, whereas POE2 stimulates renin
release indirectly via the macula densa.
Three major renal tissues have been reported to contain
cyclooxygenase and be capable of PG biosynthesis: 1) the
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Fig. 3. Effect of pro staglandin E2 on renin release from afferent
arterioles alone (0; N 8) and afferent arterioles withnacula densa
attached •; N = 8). *p < 0.02 compared with the time control group.
vasculature including glomeruli, 2) the collecting tubule and 3)
the medullary interstitial cells [19]. The renal vasculature is the
main tissue that synthesizes PG!2 [8, 9], and it has been
suggested that compartmcntalization of PG!2 synthesis within
the vasculature is important for the regulation of renin release
[10], Beierwaltes et al [51 reported that in isolated rat glomeruli,
the stimulation of renin release elicited by arachidonic acid
correlates with the production of PG!2 but not PGE2. However,
since only 3 to 10% of glomeruli have their attendant afferent
arterioles in this preparation [20], most of the PGs would be
produced by the glomeruli, which could in turn influence renin
release. In the present study, the preparation of afferent arte-
rioles alone is free from all other renal tissue, and, therefore,
the results show a direct interaction between PGs and renin
release at the local level of afferent arterioles. Renin release
from microdissected afferent arterioles increased with the ad-
ministration of arachidonic acid, and this increase was com-
pletely blocked by pretreatment with azo analog 1, a PG!2
synthetase inhibitor. This may suggest that renin release may be
regulated by PGI2 which is locally synthesized in the afferent
arterioles.
PGE2 is a principal PG synthesized by renal tubular and
medullary interstitial cells [10]. It may be possible that PGE2 of
tubular and medullary origins could participate in the regulation
of renin release by altering the electrolyte transport at the
macula densa. It has been shown that PGE2 inhibits chloride
transport in the medullary thick ascending limb of the loop of
Henle [21], and Kotchen, Welch and Ott [11] proposed that
PGE2 may stimulate renin release by inhibiting absorptive
chloride transport at the macula densa. However, no previous
study has reported direct evidence for the involvement of the
macula densa portion" of the distal tubule in PGE2-induced
renin release. In the present study, PGE2 increased renin
release only in the presence of the attached macula densa. This
observation may be considered the first direct evidence that the
macula densa mediates PGE,-induced renin release. The mech-
anism by which PGE2 stimulates renin release could be due to
the inhibition of sodium chloride transport at the macula densa.
In order to suppress PGI2 synthesis, we pretreated afferent
arterioles with azo analog 1 which is reported to inhibit both
P012 and thromboxane A2 synthetases [5, 7, 22]. In rabbit
kidney slices [71 and isolated rat glomeruli [5], it is reported that
azo analog 1 suppressed PGI2 synthesis induced by arachidonic
acid, while production of PGE2 and PGF remained intact. !n
the present study, the pretreatment with azo analog 1 prevented
the increase in renin release induced by arachidonic acid.
Similar effects of azo analog 1 on renin release have also been
reported in rabbit kidney slices [7] and isolated rat glomeruli [5].
While azo analog 1 suppresses thromboxane A2 synthesis, its
effect on renin release in the present study is likely due to the
inhibition of PG!2 synthesis since rabbit renal cortex does not
synthesize detectable levels of thromboxane A2, even in the
presence of exogenous arachidonic acid [7].
Despite the fact that PGI2 is rapidly hydrolyzed to 6-keto-
PGF1,,, an inactive PG, in an aqueous solution at a physiolog-
ical pH and temperature [23], prolonged duration of PGI2-
induced renin release was observed in kidney slices [6]. It has
been proposed that such prolonged duration may be mediated
by metabolite(s) of PG!2 [24, 25]. In the present study, renin
release from afferent arterioles continued to increase during the
recovery period in both arachidonic acid and P012 groups. This
is in contrast with the observation that renin release induced by
6-keto-PGE, in the present study or isoproterenol in our previ-
ous study [13] returned toward the basal value during the
recovery period. In order to examine whether these continued
increases during the recovery period are mediated by metabolic
transformation of PG!2, we tested the effect of carba-PG!2, a
synthetic analog of PG!2. It has been shown that carba-PG!2
mimics the action of PGI2 in various preparations although it is
less potent than PG!2 (approximately one-tenth) [26—28]. During
the experimental period, carba-PGI2 (5.0 X l0— M) increased
renin release to a level similar to that caused by PG!2 (1.0 X
i0 M); however, during the recovery period renin release did
not increase further. Thus renin response induced by carba-
PG!2 was significantly less than that induced by PG!2 during the
recovery period. This result may suggest that at least part of the
renin response to PGI, is mediated by its metabolite(s).
It is not known from the present study which metabolite(s)
may be responsible for the continued increase in renin release
induced by arachidonic acid and PG!2. The only active metab-
olite known thus far is 6-keto-PGE1, which is formed from P012
and probably from 6-keto-PGF1,, via the 9-hydroxyprosta-
glandin dehydrogenase pathway [29]. The activity of this en-
zyme is greatest in the cortex and negligible in the papilla,
corresponding to the zonal distribution of renin in rabbits [24,
30]. Since 6-keto-PGE1 is more stable [29, 31] and its pharma-
cological actions are similar to PG!2 both quantitatively and
qualitatively [24, 25, 3 1—33], it has been suggested that 6-
keto-PGE1 may mediate a part of the renin-releasing action of
*
a
(V..,,
cn,-CV
a
P
400
300 -
200 -
100
0— I I
Ito et a!: Prostaglandin and renin release 1143
PGI2 [24, 25]. In the present study, 6-keto-PGE1 increased renin
release from afferent arterioles, reaching a maximum of 1.80 ng
Al. hr' . AF '/hr during the experimental period, while the
maximum induced by the same concentration of P012 was 4.50
ng Al . hr' . AF/hr (during the recovery period). Therefore,
even if we assumed that PGI2 was totally converted to 6-
keto-PGE1, the large increase in renin release during the
recovery period in the PG!2 group may not be accounted for
solely by formation of 6-keto-PGE1. However, it could be
possible that PG!2 and formed 6-keto-PGE1 acted synergisti-
cally in activating the intracellular mechanism of renin release,
leading to the larger renin release during the recovery period.
As an alternative or additional mechanism, increased renin
release during the recovery period may reflect prolonged ac-
tions of PGI2 on intracellular levels of cyclic AMP and/or
calcium.
In contrast to the present study, McGiff, Spokas and Wong
[24] and Spokas, Wong and McGiff [25] reported that in rabbit
kidney slices, 6-keto-PGE1 -mediated renin release remained
elevated during the recovery period whereas PGI2-mediated
release did not, which was more evident when endogenous
prostaglandin synthesis was inhibited. The discrepancy be-
tween their studies and ours may be due to the difference in the
experimental preparations employed; especially the presence of
tubular components may not only hamper the rinsing of added
prostaglandins but also affect their metabolism.
In conclusion, the results of the present study suggest that
arachidonic acid stimulates renin release through the formation
of PG!2 and possibly its metabolite(s) in the afferent arterioles.
These arachidonic acid metabolites act directly on the afferent
arterioles where they are synthesized. On the other hand, PGE2
stimulates renin release indirectly via the macula densa. This
may suggest that PGE2 synthesized in renal tubular or medul-
lary interstitial cells could participate in the control of renin
release by means of the macula densa.
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